On November 12, 2025, House Rx, a health tech company focused on making specialty medications more accessible and affordable for patients, announced it has raised $55 million in Series B equity and debt to expand its in-clinic specialty pharmacy model. The financing was led by New Enterprise Associates and Town Hall Ventures, and included participation from LRVHealth, First Round Capital, Bessemer Venture Partners, and Silicon Valley Bank. Wilson Sonsini Goodrich & Rosati advised House Rx on the transaction.

The Series B round brings the company's total capital raised to $100 million. The company is currently investing in several more AI capabilities which will come natively as part of its pharmacy management system.

The Wilson Sonsini team that advised House Rx on the transaction included Mark Baudler, Jocqui Kaup, Sunny Kumar, and Aletha Tarn.

For more information, please see House Rx’s news release.